Lifecore Biomedical merger receives early termination of US antitrust waiting period
LFCR•U.S. antitrust agencies ended the waiting period early on November 4, 2026, clearing one closing condition for Lifecore Biomedical’s merger. Completion remains subject to other conditions, including stockholder adoption of the agreement at a special meeting.
1. Closing condition cleared
U.S. antitrust agencies ended the waiting period early on November 4, 2026, clearing a closing condition for Lifecore Biomedical’s merger. Under the September 27, 2026, merger agreement, the company will become a wholly owned subsidiary of Lifecore; completion remains subject to other closing conditions, including stockholder adoption of the agreement at a special meeting.
